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Abbreviations
1 LUAD Lung adenocarcinoma 
2 NGS Next generat ion sequencing
3 qPCR Quantitat ive real - t ime PCR
4 RNAseq Next generat ion RNA sequencing
5 NSCLC Non-small cell lung carcinoma
6 EC Urethane (also cal led ethyl carbamate)
7 DEN Diethyl nitrosamine (also called N,N-Diethyl nitrous amide)
8. TP53 Tumor protein p53
9. MLL2 Histone-Lysine N-methyltransferase
10. CDKN2A Cyclin Dependent Kinase Inhibitor 2A
11. KEAP1 Kelch l ike ECH associated protein 1
12. PTEN Phosphatase and tensin homolog
13 KRAS KRAS proto-oncogene, GTPase 
14 EGFR Epidermal growth factor receptor
15 ALK ALK receptor tyrosine kinase
16 BASC Broncho-alveolar stem cell
17 AT Alveolar type cel l
18 PNEC Pulmunary neuroendocrine cell 
19 Kras Kirsten rat sarcoma viral oncogene homolog 
20 Trp53 Transformation related protein 53
21 GSEA Gene set enr ichment analysis 
22 CRE P1 bacteriophage CRE recombinase
23 GFP green f luorescent protein
24 CCSP Club cel l secretory protein
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25 LYZ2 Lysozyme C-2
26 SFTPC Surfactant Protein C
27 ddPCR Digital droplet PCR 
28 dNTP Deoxynucleotide
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Introduction
Lung cancer presents the deadl iest k i l ler among malignant tumours both in 
men and women with over 1.7 mil l ion deaths per year. In 2030, the incidence 
of  this dreadful disease wil l  exceed 3.7 mil l ion, according to Globocan 2018 
project ions1. Lung cancer is classif ied in two major categories: small cel l 
lung cancer (SCLC) which accounts for 15% of new cases, and non -small 
cel l lung cancer (NSCLC) accounting for another 80% (Figure 1)1. In this last 
category of  lung cancers, dif ferent subtypes are identif ied as follows: lung 
adenocarcinoma (LUAD), squamous cel l carcinoma (SCC), and large cell 
lung carcinoma (LCLC) 2 , 3.  These histological subtypes display dif ferent 
cel lular appearances, arise in dif ferent locations in the lungs, are caused by 
dif ferent main r isk factors, and display divergent mutat ion prof i les 2 - 7.
Figure 1:  His to log ic  c lass i f icat ion of  lung cancer .  The data were co l lected  f rom Bray e t  a l .  
“Global  cancer  s tat is t ics ”.  CA Cancer  J  Cl in  2018.  The p lots  were generated wi th  P r ism 
Graphpad 8 t h .
In the past,  over 10% of NSCLC were assigned to the LCLC subtype. 
Current ly, using a deeper classif icat ion of  other histological subtypes, only 
2% are diagnosed as LCLC 4. The name of  this category ref lects the absence 
of  a squamous or g landular cytology and the lack of  dif ferentiat ion of  the 
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cel ls involved. This histological subtype can be found in almost every 
locat ion in the lung 2.
Previously SCC presented the most common subtype of  NSCLC 5. I t  general ly 
local izes in the central part of the lungs, in proximity to the large airways 2 , 3.
From the molecular point of  view, SCC contains inact ivat ing mutat ions in 
var ious tumor suppressor genes such as tumor protein p53 ( TP53 ,  mutated 
in 81% of cases), histone-Lysine N-Methyltransferase (MLL2 , 20%), cycl in 
dependent k inase Inhibitor 2A (CDKN2A 15%), kelch l ike ECH associated 
protein 1 (KEAP1 12%), and phosphatase and tensin homolog ( PTEN 8%) 
(Figure 2). In addit ion, recurrent gain -of-function mutat ions have been found 
in oncogenes such as phosphat idylinositol -4,5-bisphosphate 3-kinase 
catalyt ic subunit alpha (PIK3CA ,  16%) and neurof ibromin 1 (NF1 ,  15%)4. The 
histology of  SCC is character ized by f lat and elongated cel ls that form 
mult iple layers and feature part ial kerat inisat ion and foll ic le form ation similar 
to the skin2 , 3.  The major r isk factor is smoking (direct or second -hand 
smoke), while secondary (contr ibut ing) r isk factors are thought to be 
asbestos, heredity, and radon 3 , 5.
Current ly, LUAD is the most prominent histological subtype of  lung cancer, 
accounting for over 40% of al l  cases of  NSCLC 1 , 5.  I t  tends to develop in the 
smaller airways, in proximity of  the alveolar spaces 3. The World Health 
Organization classif ies LUAD in var ious histopathologic growth patterns 
( lepidic, acinar, pap i l lary, micropapil lary,  sol id, invasive mucinous, col loid, 
fetal,  and enter ic) 3.  LUAD histology is characterized by a glandular shape 
and presents features of  mucus secret ing cel ls. Major genomic alterat ions 
are present in the KRAS proto-oncogene GTPase (KRAS ,  25-30%), 
epidermal growth factor receptor (EGFR 15-17%), and ALK receptor tyrosine 
kinase (ALK ,  4-7%) driver oncogenes. Regarding the onco suppressor side, 
TP53 (41%) is the single most mutated gene in LUAD, fol lowed by KEAP1 ,
(14%) (Figure 2)7 , 8.  LUAD risk factors are heredity factors 9, as well as 
occupational exposure to agents such as sil ica, asbestos, radon, heavy 
metals, radiat ion, and diesel fumes 2, 3.  Nevertheless, the main et iologic 
agent remains tobacco smoke9 -1 1.
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Figure 2:  Dr iver  genes mutat ions in  LUAD and SCC. Data  are co l lected  f rom the cancer  
genome at las  (https://portal.gdc.cancer.gov/) and cata logue of  somat ic  mutat ion in  cancer  
(h t tps: / /cancer .sanger .ac.uk/cosmic) . The gene names are  repor ted as HGNC 
nomenclature .  <1 mutat ion= muta t ion in  more  than one dr iver  gene.  The p lots  were 
generated wi th  Pr ism Graphpad 8 t h .
1.1. Tobacco’s carcinogens mutational signature in LUAD
The advent of  deep sequencing and transcriptome pro f i l ing opened new 
possibil i t ies to further character ize and describe LUAD. In the past 10 years 
a plethora of  sequencing studies populated the scient if ic l i terature, using as 
start ing material the cancer patient specimens. According to the concept of  
carcinogen-induced mutational s ignatures 7 -1 0,  every carcinogen tends to 
leave a specif ic imprint on normal human cel ls. This ef fect persists 
throughout the carcinogenic process and can be detected in ful ly malignant 
tumors. According to this, it  is possible ret rospect ively decipher what a 
carcinogen caused, namely a carcinogen signature 7, 8 , 1 5.  Therefore, the 
def init ion of  such carcinogen signatures has primari ly rel ied on correlat ion 
between clinically documented exposures ( i.e. smoking) and sequencing 
results from var ious human cancers 7 -1 0 , 1 3 , 1 4.  For the tobacco smoke, where 
the composit ion consists of  a complex mixture of  chemical compounds 1 1, the 
signature derived it  is the result  of  the addict ion and combinat ion of  al l  
carcinogens induced mutation present in this complex mixture. Indeed, the 
dif ferent specif ic carcinogen-induced alterat ions contr ibute with dif ferent 
patterns and weights at the whole smoking signature 9 , 1 6.  Due to the mixture 

























several mutat ional events dur ing the tumorigenesis process, i t  is not 
possible to dissect the contr ibut ion of  every single carcinogen from a ful ly 
malignant smoking-associated tumor 7 -1 0. Furthermore, the ef fect of  a single 
carcinogen is not only the genomic alterat ion that the carcinogen caused, but 
also the downstream repercussion that this genomic alterat ion wi l l induce, 
and the feedbacks that would derive f rom this event 1 7.
In consequence, a gap emerged between cutt ing -edge technology and the 
possibi l i ty of  f inely mapping the carcinogen-induced molecular alterat ions in 
the lungs. Indeed, for the tobacco smoke induced alterat ions, the necessity 
arose to develop dif ferent animal models of  carcinogen induced LUAD to 
dissect the carcinogenic effect of  the tobacco smoke in the dif ferent 
alterat ion processes related to the dif ferent carcinogens. In this matter, only 
one study (Westcott et al,  Nature 2015) attempted to def ine a specif ic 
carcinogen-induced signature and it  was l imited to only two carcinogens t hat 
could mimic the mutat ional pattern observed in humans 1 7. The remarkable 
results obtained in this study are hampered by the dif ferent stromal and 
immune- inf i l t rat ing cel ls contaminating the sequencing samples 1 8 , 1 9.
Therefore, i t  seems of  essential importance to obtain the appropriate start ing 
material for def ining a signature induced by a single carcinogen. In this 
optic, deriving a pure cancer cel l would be a good start ing point.  Despite 
that, only a carcinogen signature is not enough to precisely map the pattern 
of  mutat ion acquisit ion in the lung. I t  remains uncertain in which pulmonary 
cel l l ineage the LUAD tumorigenesis init iates.
1.2. LUAD cell lineage of origin
Dif ferent cell l ineages contr ibute to constitute the lungs airway epithel ium. In 
the lower respiratory tract,  we can recognize the respiratory epithel ium and 
the respiratory zone 2 1. The respiratory epithel ium l ines trachea, bronchi and 
bronchioles, and is composed from Goblet cells with the function of  secret ing 
mucus to protect the membrane. The ci l iated cel ls mainly dedicate to the 
mucus clearance mechanism 2 1. Among the ci l iated cel ls we also f ind the 
basal cel ls, representing the stem cel ls, or the progenitors of  the airway 
epithel ium. At the level of  terminal bronchioles, we also observe the club 
cel ls; able specif ically to secrete dif ferent k inds of  surfactants, and 
character ized by their glandular form 22. In the respiratory zone, at the level 
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of the alveoli,  we f ind alveolar macrophages and pneumocytes. In 
pneumocytes, we recognize alveolar type 1 (AT1) and alveolar type 2 (AT2) 
subtypes2 1.  AT1 cel ls are devoted to the gas exchange, their shape is 
typical ly squamous with a thin wall and a f lat shape. The AT2 cel l are 
cuboidal and their funct ion is related to the production of  lung surfactant.
Pulmunary neuroendocrine cell (PNEC) and variant c lub cel l complete the 
lung histology2 2 (Figure 3).
In patients, LUAD stains posit ive for markers of  AT2 cell and club cells with 
antibodies detect ing surfactant protein C (SPC) and secretoglobin family 1A 
member 1 (SCGB1A1)2 3.  These f indings gave r ise to the hypothesis that AT2 
cel ls were the LUAD cel ls o f  origin. To elaborate on this hypothesis, most 
scientists deployed dif ferent transgenic mouse models mainly based on the 
point mutat ions in KRAS codon 12/13 2 4 - 2 6.  These mutat ions, that represent 
the most common in KRAS dr iven LUAD in human 2 7, lead to the oncogenic 
form of KRAS. With these animal models,  using dif ferent CRE drivers, it  is 
possible to induce the expression of  the oncogenic KRAS in dif ferent cell 
l ineages2 4- 2 6 ,  2 8.  Having as target the AT2, the f irst studies focused their 
attention on this ce l l  l ineage and Broncho-alveolar stem cells (BASC) that 
stained posit ive to AT2 and club cell markers 25.  Another study had as 
investigat ion target the club cel ls using the same approach to try to resolve 
the implicat ion of  this l ineage in the LUAD tumorigen esis2 8.  Both studies 

























Figure 3: Cells of the lungs: schematic 
representation of different cell lineages 
composing the respiratory epithelium. In 
brackets are reported the different 
specific marker per cell lineage. 
Broncho-alveolar stem cell 
(BASC);Bronco-alveolar ductal junct. 
The figure was readapted from 
Sutherland KD.,Berns A.”Cell of origin of 
lung cancer”.Molecular Oncology 4, 397-
403 (2010).
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tumorigenesis process , but ful l  mal ignancies arose exclusively f rom AT2 
cel ls and other cel l l ineages gave r ise only to hyperplasia 2 5 , 2 8.  An uncharted 
matter in this approach is to detect the smoked induced LUAD cell of  origin. 
This cannot be achieved using a genetic model, where al l the series of  
events related to smoking and tumorigenesis are not recapitulated and 
neither possibly recaptured 7, 8 , 1 2 , 1 7.
In summary, the state of  the art in smoking -induced LUAD consists of  an 
unknown init iat ing cel l l ineage, a mutat ional prof i le accounting as key 
mutation KRAS and TP53 genes, and a location in the lung at the level of  the 
small airways in proximity of  the alveolar space. In this context our group 
established a specif ic and pivotal way to induce LUAD in mice 3 0. We also 
used a combination of  genetical ly induced mouse models, and/or dif ferent 
tr iggering carcinogens to recapitulate early event of  thoracic 
malignancy3 0, 3 1.  On behalf  of  that, we are in the posit ion of  combining 
dif ferent exper imental approaches to tackle the identif icat ion of  the smoked 
induced LUAD cel ls of  origin and def ine specif ic carcinogen induced 
signatures. In this broad topic, I  focused on a metho d to map early events of  
alterat ions in the lung, af ter the carcinogen insult ,  and prof i led the 
transcript ional pattern of  pure cancer cel l  l ines der ived f rom dif ferent 
carcinogens. 
1.3. Aim
The aim of  this dissertat ion is to combine dif ferent approaches for mapping 
alterat ions induced by tobacco smoke carcinogens dur ing LUAD 
tumorigenesis. In our research group, we achieved to induce LUAD with 
dif ferent carcinogens in suscept ible mouse strains. Using those dif ferent 
models of  carcinogen-induced LUAD, this thesis aims to:
a) Map the gene expression prof i les of carcinogen induced LUAD cel l
l ines established using inject ion of two dif ferent tobacco carcinogens
into two dif ferential ly suscept ible mouse strains.
b) Identify the cel lular origin of LUAD using mouse models of respiratory
epithel ial cel l fate.
13
2. Publication I: Tobacco chemical-induced mouse lung
adenocarcinoma cell lines pin the prolactin orthologue proliferin as a
lung tumour promoter
2.1. Summary
LUAD represents the most common histological subtype of  and the most 
f requent cause of  death f rom non-small cel l lung carcinoma (NSCLC), 
accounting for over 600,000 deaths per year wor ldwide 1. As is also true for 
other histological subtypes of  NSCLC, smoking r epresents the main cause of  
LUAD. The molecular prof i le of  this disease is completely dif ferent in 
smokers compared with never smokers, carrying over ten t imes the amount 
of  mutat ions as wel l as a unique transcr iptome 7 , 1 3 , 3 3.  The need for faithful 
models of  smoking-induced LUAD that ful ly recapitulate the biological 
behavior and the molecular prof i le of  LUAD is unmet. 
Hence, mouse models of  tobacco carcinogen-tr iggered LUAD were selected 
for our purposes, and we induced LUAD in two dif ferent strains of  i nbreed 
mice: FVB and Balb/c, using two dif ferent carcinogens of  tobacco smoke: 
urethane and diethyl nitrosamine, applied according to established protocols. 
Al l mice developed large tumors that, after histological conf irmation, were 
used to establ ish truly malignant carcinogen-induced LUAD cel l l ines (n = 7). 
Independent f rom which carcinogen was used, al l  cel l l ines were harbor ing 
mutations in Kras and Trp53 genes. They are mouse homologs of  two of  the 
most relevant altered human genes in smokers’ LUAD ( KRAS and TP53)7.  Al l 
cel l l ines were immortals, phenotypical ly stables and indef initely 
prol iferat ives in v itro .  Those cel l l ines were able to cause, through 
subcutaneous, intravenous, and intrapleural inject ion, pr imary sol id tumors 
at the inject ion site and lung metastases in syngeneic mice, which were 
uniformly lethal.  
Gene expression prof i l ing of  our carcinogen induced LUAD cel l l ines, in 
comparison with naive mouse lungs and various other cel l types (alveolar 
epithel ial cel ls, immune cel ls, and other cancer cel l l ines), revealed a unique 
gene expression signature. This transcriptomic f ingerprint featured 
stat ist ically signif icant alterat ions in key pathways for cancer development, 
such as DNA replicat ion, purine metabol ism, and mitot ic checkpoint 
regulat ion. Interest ingly, the carcinogen-induced LUAD cel l l ine signature 
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suff iced to precisely dichotomize normal from cancer samples f rom the 
Biomarker- integrated Approaches of  Targeted Therapy for Lung Cancer 
El imination (BATTLE) study 3 5. Moreover, gene-set enrichment analysis 
disclosed a strong posit ive enrichment of  the LUAD cel l l ine transcr iptomic 
signature among smokers’ patients and a signif icant negative enrichment 
among never smokers’ f rom the BATTLE dataset. 
In conclusion, our carcinogen- induced cel l l ines are able to closely mimic 
smokers’ LUAD in terms of biological behavior and molecular prof i le, 
represent ing a new tool to study the pathobiology of  this disease.
2.2. Contribution
My personal contr ibut ion to this publ icat ion consisted of  def ining the 
transcriptome prof i le of  the dif ferent carcinogen -induced LUAD cell l ines, 
revealing the unique transcriptomic signature of  those cel l l ines and cross -
examining those results with a publicly avai lable dataset of  human LUAD 
transcriptomes. For this purpose, we performed gene expression prof i l ing 
using Affymetr ix Mouse Gene 2.0 ST Arrays and analyzed the samples l isted 
below using dedicated sof tware (Transcr iptome analysis console 4, TAC4; 
Thermo Fisher Scientif ic,  Waltham, MA): 
Tobacco carcinogen-induced LUAD cel l l ines (n = 6)
Lung from naive syngeneic mice (n = 4)
Mouse type II  alveolar epithel ial cel ls (n = 5)
Mouse airway epithelial cel ls (n = 4)
Mouse mast cells (n = 4)
Mouse macrophages (n = 4)
Other murine cancer cel l l ines (n = 4)
The results of  the above analyses are vis ible in f igure 4A of  the publ icat ion. 
Af ter gene expression prof i l ing, I  performed pathway and gene -set 
enrichment analyses (GSEA) (f igures 4E and 4F). Pathway analysis was 
performed using the WikiPathway function of  TAC4. GSEA was performed 
using GSEA4 (Broad institute; avai lable at https://www.gsea -
msigdb.org/gsea/index.jsp). To cross -val idate the carcinogen-induced LUAD 
cel l l ine signature in human LUAD transcr iptomes, I  der ived f rom our mouse 
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gene l ist the relat ive human orthologs using OrthoDB, and other relevant 
webtools. This “humanized” gene l ist was then used for two dif ferent 
purposes:
As a metr ic of  distance to compute hierarchical c lustering between
human LUAD transcr iptomes and matched normal lung t issues.
To build a custom gene-set and analyze its enrichment in
transcriptome prof i les of  smokers’ and never smokers’ LUAD.
































3. Publication II: Club cells form lung adenocarcinomas and maintain the
alveoli of adult mice
3.1. Summary 
Lung cancer and chronic lung diseases represent a major health problem and 
are caused by the inhalat ion of  noxious substances, such as tobacco smoke. 
LUAD is mainly caused by chemical tobacco smoke carcinogens that induce 
alterat ions of  KRAS in st i l l  unknown pulmonary cel ls 7 , 9 , 1 0 , 3 2.  Previous 
studies of  pulmonary l ineage tracing have ident if ied as LUAD progenitors 
both airway and alveolar cel ls 2 3 , 2 9.  However, al l  those studies suffered of 
the pecul iar promiscuity or incomplete lung cell l ineage labe l ing of the 
exist ing l ineage tracing mouse models. This resulted in fai l ing in the 
complete ident if icat ion of  al l  cel ls belonging to a given l ineage (false 
negative marking) or detect ing other cel ls outside of  the target l ineage (false 
posit ive marking). Moreover, exist ing studies that tr ied to address the 
cel lular or igins of  LUAD used genet ically engineered mouse models based 
on the overexpression of  oncogenes such as KRASG 12 D in the lungs2 3, 29.
Recently, i t  was shown that these genetic models do not mimic the 
mutat ional prof i les of  human LUAD as well as of  chemical - induced mouse 
models1 8.  Using the more human-relevant carcinogen-tr iggered LUAD 
models, we aimed to def ine the cel l l ineage/s that init iate tumorigenesis. For 
the purpose of  cell l ineage label ing, we crossed a CRE-reporter mouse strain 
that switches somatic cel ls f rom membranous mt/td Tomato to membranous 
GFP upon CRE-mediated recombination 36  with six dif ferent CRE-driver 
strains. This al lowed permanent and accurate label ing of  dif ferent lung cel l 
l ineages. Moreover, the co-local izat ion of  GFP-label ing with cel l l ineage 
protein markers showed that GFP in CCSP-CRE mice marks al l airway 
epithel ial cel ls including club and ci l iated cel ls. In the same way, GFP in 
LYZ2-CRE mice marks some alveolar type 2 cel l and alveolar macrophages. 
We next induced LUAD with urethane (also known as ethyl carbamate, EC) 
or 3-methylcholanthrene inject ions. Both carcinogens were able to give r ise 
to preneoplast ic lesions and neoplasia located in airways and in the alveolar 
regions. Amazingly, al l tumors of  GFP;CCSP-CRE mice showed GFP-labeled 
airway cel ls that did not express the club cel l marker CCSP but acquired the 
expression of  alveolar epithel ial markers SFTPC with or without LYZ2. These 
results were then recapitulated using a single urethane hit  on GFP;CCSP -
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CRE, GFP;SFTPC-CRE, and GFP;LYZ2-CRE mice backcrossed to the 
suscept ible FVB strain, which develops human-l ike alterat ions l ike 
KRASQ6 1 R. We then established and appl ied digital droplet PCR (ddPCR) to 
detect in which lung l ineage the KRASQ 61 R arose at ear ly t ime points af ter 
single urethane exposures. To enable the simultaneous detect ion of  KRAS 
and CRE-cassette status, an ad hoc technical assay was designed and 
tested. One week past the EC hit ,  both GFP; CCSP-CRE and GFP;LYZ2-CRE 
mouse strains showed KRASQ 61 R mutations, but KRASQ6 1 R mutations
select ively persisted in GFP-labeled airway cel ls in the lungs of  GFP;CCSP-
CRE mice at two weeks. In summary, we addressed in this publ icat ion the 
accomplice role of  airway epithel ial cel ls,  and more specif ical ly of  club cel ls, 
as cel ls of  origin in LUAD.
3.2. Contribution
My personal contr ibut ion to the publicat ion consisted in developing an assay 
to quantitat ively, spatial ly, and longitudinal ly def ine the presence of  Kras 
mutations in carcinogen-induced mouse models of  LUAD. Among dif ferent 
possibil i t ies, we decided to ut i l ize Digital droplet polymerase chain react ion 
(ddPCR)37. W ith a standard ddPCR assay it  is possible to analyze a single 
genetic condit ion per experiment. My contr ibut ion was to repurpose this 
assay with a new approach to al low the detect i on of  two dif ferent genetic 
condit ions with a single assay and analyze the relat ive data. A detailed 
overview of  technical method, stat ist ical and analyt ical approaches 
implemented are provided in Appendix A. The ddPCR custom primers and 
probe are descr ibed in Spella, M. et al .  2019 materials and methods. The 



























































































From the publ icat ions included in this dissertat ion it  becomes evident that a 
broad range of  mouse and in v itro models was implemented to study 
carcinogen-induced alterat ions in the lungs. I t  was demonstrated how 
chemical carcinogenesis can be used to deep en our current understanding of  
LUAD. Moreover, a new version of  a cutt ing -edge technology was 
implemented (ddPCRA dv) and adapted to mouse models of  tobacco - induced 
LUAD.
The generation of  seven carcinogen- induced LUAD cel l l ines f rom 
carcinogen-induced tumors in dif ferent mouse strains was presented in the 
f irst publ icat ion. These cel l l ines represent a mult itasking tool to study 
dif ferent aspects of  smoking -induced LUAD since they are able to mimic the 
dif ferent aspects of  tumors-init iat ing cel ls and to exhibit  a ful ly malignant 
state. Furthermore, due to their gene expression prof i les and mutational 
burden in key cancer genes overlapping with smoker’s LUAD prof i les, these 
cel l l ines epitomize a road map to study the dif ferent aberrat ions induced by 
tobacco carcinogens. As shown in the publ icat ion, these cel l l ines presented 
a unique gene expression prof i le that is not only displaying cancer related 
deregulat ion but also suggests the existence of  specif ic carcinogen 
signatures. This possibi l i ty is examined in depth in a study st i l l  unpubl ished, 
in which our col lect ion of  cell l ines was expanded to a larger number. We 
used dif ferent mouse strains and carcinogens, which were subsequently 
deployed in order to develop a new approach based on RNAseq. We were 
able to f ingerprint,  in this study, the carcinogen -induced mutat ion status and 
gene expression prof i les of  our cel l l ines.  
In the second publ icat ion, the role of  club cel ls in LUAD carcinogenesis was 
elucidated. Using dif ferent combinat ions of  cell l ineage la beling, i t  became 
possible to pinpoint the role of  airway cel ls in LUAD development. The use of  
ddPCRA d v  elucidated the persistence of  Kras mutation in club cel ls dur ing 
early steps of  carcinogenesis. Furthermore, the combination of  cell l ineage 
label ing and ddPCRA dv  permitted for the f irst t ime analyses of  mutat ional 
processes in space and t ime on the single copy level.  Consistent with the 
tumor init iat ion phase, where a mutat ion arises in a cel l and is clonally 
expanded among its progeny, this approach al lowed us to f inely track the 
development of  a mutat ion in a specif ic cel l l ineage and to quantitat ively 
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assess its expansion over t ime. Expanding the spatial and longitudinal 
mapping from one single mutat ion to the ful l  spectrum of  carcinogen - induced 
mutations would require an experimental approach designed toward the 
massive paral lel sequencing. Nevertheless, the approach described in Spel la 
et al 2019 opens a targeted path for further explorat ions. 
In conclusion, this dissertat ion combines dif ferent biological approaches 
designed to map and character ize tobacco carcinogen - induced alterat ions in 
the lungs. Importantly, the relat ive contr ibut ions of  the candidate towards the 
two included publ icat ions were cr it ical in showing the faithful mimicry of  
smokers’ LUAD by our carcinogen - induced cel l l ines in the f irst manuscript,  
and in proving the early persistence of  Kras mutations specif ical ly in airway 
epithel ial cel ls in the second manuscr ipt.
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Appendix A
The ddPCR is a rel iable and powerful method that al lows detect ion and 
quant if icat ion of nucleic acids with except ional sensit ivity and high 
accuracy3 2. The ddPCR method is based on a single PCR reaction trapped 
inside an oil droplet and the usage of  f luorescent label ed ol igos (TaqMan® 
probe) to ident ify a specif ic DNA fragment. In general,  the ddPCR react ion is 
set up as a duplex PCR, where one TaqMan® probe is designed to target the 
region of  interest (ROI) and a second one for any standard reference 
f ragment (REF).The two TaqMan® probes are always label ed with two 
dif ferent f luorophores to al low the dif ferential detect ion (Figure 4).
Figure 4:  ddPCR workf low overv iew (adapted f rom Mazaika E.  e t  a l .  2011)
For our purposes, we wanted to overcome the technological l imitat ion of  two 
detect ions (one ROI and one REF), and be able to detect and quantify two 
dif ferent ROI with their relat ive REF, for a total of  four dif ferent detect ions, 
in the same ddPCR reaction. For this aim, we had to tackle three major 
tasks:
139
• To perform ddPCR on a single genome copy
• To ident ify a ROI-REF couple with one single TaqMan® probe
• To quantify two dif ferent f ragments emitt ing the same f luorescence
wavelength
Performing the ddPCR on a single genome copy
For prepar ing a ddPCR assay, the researcher needs to set up a PCR 
reaction (composed by DNA template material,  buf fer, dNTPs, primers, and 
DNA polymerase plus the two TaqMan® probes). The number of  total 
droplets prepared per reaction is 20,000. To achieve f i l l ing every droplet 
with a single genome copy, the researcher needs to know the weight in 
grams of  the specif ic species’ genome s/he is analyzing. According to this 
principle, the sample weight should be equal to the weight of  20,000 genome 
copies. Despite preparing the sample according to the above, it  is unl ikely 
that a perfect distr ibut ion of  one single genome copy per droplet can be 
achieved. To overcome this issue, I  succeeded in def ining the dif ferent 
f luorescence emitted from an empty droplet respect ive to a loaded one. This 
procedure was set up based on comparisons between a droplet loaded with 
the full ddPCR react ion and another missing the DNA template. In this way, I  
was able to quant ify the specif ic f luorescence of  a droplet missing the 
template and def ine the gating threshold.  Combining this approach with the 
maximal number of  droplets per react ion, I  was able to precisely def ine the 
number of  empty or loaded droplets (Figure 5).
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Figure 5:  Empty droplet  gat ing.  On the le f t ,  a  representat i ve p lo t  o f  no template sample is  
shown;  on the  r ight ,  a  representat i ve p lo t  o f  a  DNA - loaded sample is  depic ted.  The red  
box shows the speci f ic  gat ing threshold used.
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Identifying a ROI-REF couple with one single TaqMan® probe
In general,  a TaqMan® probe has the size and a melt ing temperature 
(depending on base composit ion and length of  the probe) compatible with the 
primer set. The modulat ion of  these two parameters is the key to al low a 
dif ferential anneal ing of  a TaqMan® probe to two dif ferent DNA fragments. 
Given the fact that the TaqMan® probe wi l l anneal specif ical ly to one 
f ragment, the unspecif ic annealing to the second fragment rel ies on a 
sequence homology exceeding 85% with the unspecif ic target sequence and 
an annealing temperature of  2 -40C lower than the opt imal one (depending on 
TaqMan® probe sequence composit ion). Combined with the droplet 
technology, this approach al lows ident if icat ion of  a ROI -REF couple (Figure 
6).
Figure 6:  Iden t i f icat ion and gat ing of  d i f ferent  emiss ion spect ra of  a  TaqMan probe:  shown 
on the top is  the  channe l  ampl i tude  p lot  and in  the bot tom the d roplet  f requency p lo t .  
Boxes represent  in  red the empty d roplet  gat ing,  in  b lack the unspeci f ic  f luorescence 
gat ing,  and in  ye l low the  speci f ic  f luorescence gat ing.
When this approach is extended to two TaqMan® probes with dif ferent 
f luorophores, it  becomes possible to identify four dif ferent f ragments (two 
ROI-REF couples).
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Quantifying two different fragments emitting the same fluorescence
All ddPCR analysis sof tware solut ions are based on the qua nt i f icat ion of  
f luorescent droplets.  Although with such sof tware I was able to identify two 
dif ferent f ragments emitt ing the same f lorescence, quantif icat ion was not 
possible, due to the several combinations of  f luorescence thresholds to 
examine (Figure 7) .
Figure 7:  2D ampl i tude p lot  depic t ing the d i f feren t  combinat ions of  f luorescent  droplets :  
every box wi th  a d i f feren t  co lor  and le t ter  label l ing represents a d i f ferent  threshold;  
unspeci f ic  (U) ,  pos i t ive (+) ,  and negat ive  ( - ) .
To analyze all dif ferent combinat ions of  droplet f luorescence I developed an 
R language computat ional scr ipt.  This script is based on the formula
   = ( + ) −
Where:
x= n droplets posit ive for the f irst TaqMan® probe (specif ic and unspecif ic)
y= n droplets posit ive for the second TaqMan® probe (specif ic and 
unspecif ic)
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Z= n of  empty droplets
The possible combination of  thresholds (x and y) were calculated using the 
formula
, =  !! ( − )!
This approach al lowed to specif ically quantify the 7-specif ic combinations of  
f luorescence for each f ragment (both REF and ROI).
With the implementat ions of  al l  these approaches, I  repurposed ddPCR for 
our specif ic aims. For further reference to this technical ly advanced ddPCR I 
wi l l  use ddPCRAdv.
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Spatial and longitudinal quantification of KrasQ61R mutation
After developing and test ing the ddPCR A d v,  I  appl ied it  to quantify the 
KrasQ6 1 Rmutat ion over t ime and specif ically detect in which cel l l ineage it  
aroused. For these purposes, we selected GFP;CCSP-CRE, and GFP;LYZ2-
CRE mice on the FVB background, as sources for airway epithel ial - labeled 
cel ls, and the second alveolar epithel ial - labeled cel ls, respectively. Urethane 
was used to induceKrasQ 6 1R mutat ions. The injected mice were divided in two 
cohorts, one of  which was harvested one week (GFP;CCSP -CRE, n=5 and 
GFP;LYZ2-CRE, n=5) af ter the inject ion and another that was sacrif iced two 
weeks af ter the inject ion (GFP;CCSP-CRE, n=5 and GFP;LYZ2-CRE, n=5). 
The goal of  this experiment was to detect simultaneously:
Kras status (ROI=KrasQ 6 1R  and REF=KrasW i ld Ty p e)
mt/mg locus status (Rosa locus status) in CRE-reporter strain
mt/tdTomato mice (ROI=mt and REF=mg) (Figure 5)
Figure 7:  schemat ic  d iagram o f  themt/mg locus: f rom top to  bot tom is  shown the CRE 
recombinase act ion .  Act in  B core p romoter  (pCA) ,  mt /Tomato(mt)  in  red,  green f lorescent  
prote in  gene (mg) in  green,  Cre recombinase (CRE) in ye l low.  The  f igure  is  readapted f rom 
Muzumdar,  M.  D.  e t  a l  2007
For this ddPCRA d v, a specif ic TaqMan® probe was conceptual ized and 
designed to detect mutat ions in the Kras gene (ROI-REF couple 1) and the 
cel ls in which it  occurred (green or red labe led) (ROI-REF couple 2) (Spel la 
M. et al 2019 mater ials and methods). In this way, a spat ially and
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quantitat ive def init ion of  the Kras status could be obtained. Subsequent ly, I  
analyzed the trend over t ime f inal ly al lowing us to address the Kras status 
longitudinal ly.  
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